People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TearClear Corp. | — | Pharmaceuticals | Series B | $52.4M | $122.6M | 2017 |
| SLAM BioTherapeutics, Inc. | — | Biotechnology | Series A | $9.2M | $2.6M | 2023 |
Steve Pazol at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve Pazol on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Heinick | 2 | 3 |
| William Link | 1 | 11 |
| Tyler Stowater | 1 | 7 |
| Richard Harrison | 1 | 6 |
| Robert Bailey | 1 | 4 |
| Robert Dempsey | 1 | 2 |
| Stuart Raetzman | 1 | 2 |
| Jeffry Weinhuff | 1 | 1 |
| Kevin Hershfield | 1 | 1 |
| Ted Schwartz | 1 | 1 |
| Mark Hagler | 1 | 1 |
| David Vennettilli | 1 | 1 |
| Theodore Schwartz | 1 | 1 |
| Steve Potts | 1 | 1 |
| Srini Venkatesh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.